Test a new pill plus abemaciclib versus standard therapy
Part of Cancer, Skin clinical trials.
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ER-positive and HER2-negative breast cancer confirmed by a lab test
- Your cancer has spread or is locally advanced, and it showed progression while on an aromatase inhibitor (AI)
- Your tumor is confirmed to have an ESR1 mutation (from a blood liquid test or from tumor tissue)
- Your cancer has not progressed for at least 6 months on an AI plus a CDK4/6 medicine (palbociclib or ribociclib)
- You can take tablets and are well enough for treatment (ECOG 0–1), with blood and organ counts that meet study limits
- If you have brain metastases, they must be treated, not causing symptoms, not needing steroids, and stable for over 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.